Cancer doctor, investment firm to build Seaport District biotech tower
The venture said it bought its first property, a 1-acre development site at 105 West First St. in the Seaport District, for $80 million.
(Bloomberg) — A deal-making cancer doctor who sold his pharmaceutical company for almost $12 billion is launching a real estate venture to bolster the growth of the biotechnology industry.
Arie Belldegrun’s family office, Bellco Capital, has entered into a joint venture with New York-based real estate developer Tishman Speyer to start Breakthrough Properties, the companies said Tuesday in a statement. The venture said it bought its first property, a 1-acre development site at 105 West First St. in the Seaport District, for $80 million, and is exploring other acquisitions in the area as well as in San Francisco.
“This came out of necessity,’’ Belldegrun said in a telephone interview. “I realized that there’s a significant need for an ecosystem in life sciences where scientists can work and interact.’’
Belldegrun, 69, is a UCLA-based cancer researcher and surgeon who’s emerged as a serial entrepreneur and venture capitalist. He sold Kite Pharma, which develops genetically engineered cancer treatments, in 2017 to Gilead Sciences Inc. for $11.9 billion and since then has helped launch Vida Ventures to start more pharma companies.
Breakthrough Properties will provide various business development services to help tenants grow, Belldegrun said. Vida Ventures, his venture capital arm, may also take stakes in the biotech firms. The Seaport District site comes with 250,000 square feet of development rights and is expected to be finished by 2021, according to the statement.
Breakthrough’s chief executive officer is Belldegrun’s son Dan, who worked for Tishman Speyer for several years. Belldegrun’s wife, Rebecka, who is also a doctor, manages Bellco Capital, the family office formed in 2003.
The deal marks a foray into life sciences development for Tishman Speyer, which plans to hold onto the properties for the long term, according to CEO Rob Speyer. The venture will initially focus on the United States — with its sights set on cities including San Francisco, Los Angeles, and New York — but ultimately has plans to expand globally, he said.
“The last thing a life sciences company should be worrying about is real estate, and we can take that concern off the table for them,’’ Speyer said in an interview. “We’re going to focus on strategic cities that have biotech companies, leading universities, and quality housing options.’’
Tishman Speyer, whose properties include New York’s Rockefeller Center, last year sold a 13-story building in Boston’s burgeoning Seaport District for $450 million, setting a record for an office transaction in the city.
To comment, please create a screen name in your profile
To comment, please verify your email address
Conversation
This discussion has ended. Please join elsewhere on Boston.com